To gain greater understanding of the point(s) in brain glucose metabolism impacted by APOE genotype, we performed glucose tolerance tests (GTTs) and insulin tolerance tests, and we looked for relationships between these parameters and markers of AD-related pathology, including reduced membrane trafficking of GLUT1, Tau hyperphosphorylation, and interleukin-1β (IL-1β) expression. The gene discussed is MAPT; the disease is Alzheimer disease.